Recent Advances in Chemoprevention of Cancer
- 7 November 1997
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 278 (5340) , 1073-1077
- https://doi.org/10.1126/science.278.5340.1073
Abstract
Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Recent advances in our understanding of the mechanisms of carcinogenesis have led to the synthesis of new drugs that can inhibit tumor development in experimental animals by selective action on specific molecular targets, such as the estrogen, androgen, and retinoid receptors or inducible cyclooxygenase. Several of these agents (including tamoxifen, 13-cis-retinoic acid, retinyl palmitate, and an acyclic retinoid) are clinically effective in preventing the development of cancer, particularly in patients who are at high risk for developing second primary tumors after surgical removal of the initial tumor.Keywords
This publication has 29 references indexed in Scilit:
- Chemoprevention of CancerScientific American, 1996
- Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and RaloxifeneScience, 1996
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences, 1996
- Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic AcidJNCI Journal of the National Cancer Institute, 1996
- Suppression of Retinoic Acid Receptor–β in Premalignant Oral Lesions and Its Up-Regulation by IsotretinoinNew England Journal of Medicine, 1995
- ChemopreventionCA: A Cancer Journal for Clinicians, 1995
- Enhancement of Regression of Cervical Intraepithelial Neoplasia II (Moderate Dysplasia) With Topically Applied All- trans -Retinoic Acid: a Randomized TrialJNCI Journal of the National Cancer Institute, 1994
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994
- Biomarkers as Intermediate End Points in Chemoprevention TrialsJNCI Journal of the National Cancer Institute, 1990
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986